1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNatural History Studies Grant Program (Orphan Products Natural History Grants) is sponsored by Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Natural History Studies Grants Program | FDA Skip to in this section menu Medical products for rare diseases and conditions Grant Programs to Support Development of Medical Products for Rare Diseases Orphan Products Grants Program Natural History Studies Grants Program Orphan Products Grants Program About the Natural History Studies Grants Program Unlike common diseases, there is little existing knowledge on the presentation, major limitations on day-to-day function, core unmet needs and course of most rare diseases which makes drug development challenging.
To address this, it is critical to study the natural history of rare diseases. The FDA has funded natural history studies since 2016, to help address significant unmet medical needs for patients with rare diseases where there is often little knowledge on the progression of many rare diseases which makes medical product development challenging.
The information obtained from a natural history study can play an essential role in addressing these challenges, such as identifying the patient population or developing clinical outcome assessments and biomarkers for a given disease. What is a natural history study? Natural history studies look closely at how specific diseases progress over time.
A natural history study is a preplanned, observational study intended to track the course of the disease. Its purpose is to identify demographic, genetic, environmental and other variables (e.g., treatment modalities, concomitant medications) that correlate with the disease’s development and outcomes.
Information obtained from a natural history study plays an essential role at every stage of product development, such as identifying the patient population, identifying or developing clinical outcome assessments and biomarkers and, when appropriate, serving as external controls. Natural history studies are observational and non-interventional in nature and may be retrospective or prospective.
More background and definitions The natural history of a disease is the natural course of a disease from the time immediately prior to its inception, progressing through its pre-symptomatic phase and different clinical stages to the point where the disease has ended without external intervention.
Natural history studies track the course of disease over time, identifying demographic, genetic, environmental, and other variables that correlate with its development and outcomes in the absence of treatment. Thorough understanding of disease natural history is the foundation upon which a clinical development program for drugs, biologics, medical foods or medical devices is built.
Rare diseases , as defined in the U.S. Orphan Drug Act (ODA), are diseases or conditions with a prevalence of fewer than 200,000 persons in the U.S. Though individually rare, together there are ~30 million Americans affected by 7,000 known rare diseases.
Unlike common diseases, there is little existing knowledge on the natural history of most rare diseases, which makes natural history studies of particular importance for rare diseases product development. For more information, see the draft guidance: Rare Diseases: Natural History Studies for Drug Development . Types of natural history studies Retrospective study : data have already been generated prior to study initiation.
Retrospective studies are most commonly reviews of medical records, such as patient charts. Prospective study: data are generated after study initiation. Prospective studies allow implementation of a predefined and consistent data collection, up-to-date medical terminology and standard of care and the flexibility to collect additional data as the study evolves.
Survey study: collects and analyzes natural history data through questionnaires answered by patients, primary caregivers, and/or others. Survey studies typically do not involve clinical visits and provide a quick overview of the disease population. This program is intended to fund well-designed, protocol-driven natural history studies that address knowledge gaps, support clinical trials and advance rare disease medical products.
OOPD currently awards new natural history study grants every two years. OOPD is focusing efforts to support efficient and innovative natural history studies that advance medical product development in rare diseases and conditions with unmet needs. For a list of grants awarded, see: Orphan Products Grants Awarded .
Resources for applicants and grantees Grants program contact info
According to the current listing, eligibility includes: Organizations conducting natural history studies for rare diseases/conditions. (Specific eligibility details should be confirmed in the official NOFO when released). Confirm the full requirements in the official notice before applying.
Natural History Studies Grant Program (Orphan Products Natural History Grants) is funded by Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Clinical Trials Grants Program (OOPD) is sponsored by Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD). Funds clinical trials evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Pharmacoepidemiological expertise in clinical trial design and analysis for rare diseases would be highly relevant.
Clinical Trials Grants Program (Rare Diseases) is sponsored by Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD). This program funds clinical trials evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. It encourages innovative and efficient clinical trial methods.
The AFID Infrastructure Grant program closes October 30, 2026. Awards top out at $50,000, they are reimbursable, and only a political subdivision can apply. The August round put $507,000 into 14 projects at an average of about $36,000.
Read articleThe Cold Chain Grants for Emergency Food Assistance Program closes October 1, 2026, funding cold storage equipment at up to $200,000 per project with a 10% cash match. But USDA is not awarding to food banks — it is awarding to nonprofit intermediaries who will run competitive subaward programs. Two audiences, two entirely different jobs, and one of them has 43 days.
Read articleMissouri's Department of Agriculture has reopened its Urban Agriculture Cost-Share Grant — reimbursing 75% of project costs up to $10,000, with applications due September 15, 2026. A companion Food Insecure Cost-Share Grant closes August 26. Here is how these small, fast state grants work, who qualifies under the Census 'urban area' definition, and how to layer them with the federal USDA Urban Agriculture and Innovative Production program for a durable urban-farming funding strategy.
Read article